Dry Eye Dx and Tx: Tech’s Role in Modern Dry Eye Diagnostics - Scorecard - MDSpire

Dry Eye Dx and Tx: Tech’s Role in Modern Dry Eye Diagnostics

Discover how technological advancements are refining dry eye disease evaluations and improving patient outcomes.

  • By

  • TIFFANY ANDRZEJEWSKI, OD

  • September 1, 2025

  • 5 min

Share

Clinical Scorecard: Dry Eye Dx and Tx: Tech’s Role in Modern Dry Eye Diagnostics

At a Glance

CategoryDetail
ConditionDry Eye Disease (DED)
Key MechanismsVariable presentation and complex pathophysiology; tear film instability; ocular surface inflammation.
Target PopulationIndividuals experiencing symptoms of dry eye disease.
Care SettingOphthalmology and optometry clinics.

Key Highlights

  • Technological advancements improve objectivity and efficiency in DED evaluations.
  • Noninvasive tear breakup time (NIBUT) is recommended over traditional TBUT.
  • Tear osmolarity and inflammatory biomarkers are key indicators of DED.
  • AI and wearable technology are emerging tools for real-time monitoring and diagnosis.
  • Combining objective measurements with clinical expertise enhances patient outcomes.

Guideline-Based Recommendations

Diagnosis

  • Use NIBUT with a cutoff of < 10 seconds for DED diagnosis.
  • Measure tear osmolarity; values > 308 mOsm/L indicate instability.

Management

  • Utilize point-of-care tests for MMP-9 to assess inflammation.

Monitoring & Follow-up

  • Employ interferometry to analyze lipid layer thickness and meibography for gland assessment.

Risks

  • False negatives may occur with MMP-9 tests in mild to moderate DED.

Patient & Prescribing Data

Patients with symptoms of dry eye disease.

Targeted treatments based on specific DED mechanisms improve quality of life.

Clinical Best Practices

  • Incorporate advanced diagnostic technologies for accurate assessments.
  • Combine objective data with patient symptomology for tailored treatment plans.

References

Original Source(s)

Dry Eye Dx and Tx: Tech’s Role in Modern Dry Eye Diagnostics

  • by TIFFANY ANDRZEJEWSKI, OD

  • September 1, 2025

Related Content

Dry Eye Innovations

Himani Goyal, MD, discusses how advances in dry eye treatments have improved ophthalmic practice and outcomes.

  • May 1, 2026

  • 3 min
Recognizing and Treating Ocular Rosacea in Darker Skin Tones

IPL, laser, and LLLT should be chosen carefully for safety across the spectrum of skin tones.

Dry Eye Dx and Tx: Malfunctioning Mucins

Exploring the underappreciated role of mucins in dry eye disease reveals promising therapeutic avenues for improved management.